Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
AYGESTIN vs NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining. Ferrous fumarate is an iron supplement for replacement of menstrual iron loss.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
One tablet (norethindrone 1 mg, ethinyl estradiol 10 mcg, and ferrous fumarate 75 mg) orally once daily at the same time each day for 28 consecutive days, starting on day 1 of menstrual cycle.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Norethindrone: 5-8 hours (terminal). Ethinyl estradiol: 13-27 hours (terminal). Clinical context: dosing interval is 24 hours based on ethinyl estradiol half-life.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal via enterohepatic recirculation. Ferrous fumarate: iron is absorbed and incorporated; excess excreted in feces as unabsorbed.
Category C
Category D/X
Progestin
Progestin